Insight, China's Pharmaceutical Industry

TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations

TransThera Sciences (HKG: 2617) announced that China’s National Medical Products Administration (NMPA) has granted conditional...

Others

Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children

Fineline Cube Aug 7, 2026

Merck & Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration...

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Fineline Cube Aug 6, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) announced second-quarter 2026 financial results with total revenues of USD...

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Fineline Cube Aug 6, 2026

Astellas Pharma Inc. (TYO: 4503) announced first-quarter fiscal year 2026 financial results featuring revenue of...

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026

Syndax Pharmaceuticals, Inc. announced the termination of its license agreement with EOC Pharma (Hong Kong)...

Others

Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects

Fineline Cube Aug 6, 2026

Luye Pharma Group Limited (HKG: 2186) announced that its independently developed new molecular entity LY03015...

Company

RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal

Fineline Cube Aug 6, 2026

RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) released its performance forecast for the first half...

Company

Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance

Fineline Cube Aug 6, 2026

Eli Lilly and Company (NYSE: LLY) announced second-quarter 2026 financial results featuring revenue of USD...

Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of a Biologics License Application...

Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released the...

Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026

AstraZeneca plc (NYSE: AZN) and CSPC Pharmaceutical Group Limited (HKG: 1093) announced the signing of...

Company R&D

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Fineline Cube Aug 6, 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM9077, an AI-powered, potential first-in-class Target Y...

Company

BeOne Medicines Reports Record Q2 2026 Revenue of $1.7B, Driven by Brukinsa Growth and Raises Full-Year Guidance

Fineline Cube Aug 6, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced Q2 2026 financial results featuring...

Company

Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance

Fineline Cube Aug 6, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) reported financial results for the second quarter of...

Company Drug

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Fineline Cube Aug 6, 2026

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)...

Company

Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%

Fineline Cube Aug 6, 2026

Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026, with revenues...

Company Drug

CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer

Fineline Cube Aug 6, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its...

Company

Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance

Fineline Cube Aug 6, 2026

Biogen Inc. (NASDAQ: BIIB) released its second-quarter 2026 financial results, reporting revenue of USD 2.736...

Company

Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations

Fineline Cube Aug 6, 2026

Bayer AG (ETR: BAYN) released its financial results for the second quarter of 2026, reporting...

Insight, China's Pharmaceutical Industry

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations

Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects

RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal

Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

BeOne Medicines Reports Record Q2 2026 Revenue of $1.7B, Driven by Brukinsa Growth and Raises Full-Year Guidance

Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%

CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer

Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance

Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations

You Missed

TransThera Sciences Secures NMPA Conditional Approval for Tinengotinib in Advanced Cholangiocarcinoma with FGFR2 Alterations

Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook